In Brief: St. Jude
This article was originally published in The Gray Sheet
Executive SummarySt. Jude: Receives FDA approval of its new Woodridge pyrolytic carbon component production facility in Little Canada, Minnesota. The facility has the capacity to manufacture the pyrolytic carbon components for all St. Jude mechanical heart valve products , and the company will gradually increase production over the next several years. Under the terms of a 1990 supply agreement with Carbomedics, St. Jude can manufacture up to 50% of its pyrolytic carbon valve components in 1995 and up to 80% thereafter until the Carbomedics deal terminates in 1998....
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.